C-YB4UNuSirt
sirtuin activation, drug combinations, cardiometabolic health
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-YB4U
C-YB4UC-YB4Usirtuin activation, drug combinations, cardiometabolic health
0-100 chain-logic scale · 15 dimensions · scored on public evidence
This 12-week, randomized, double-blind, placebo-controlled Phase 2 study will evaluate two fixed-dose oral combinations of L-leucine, sildenafil, and metformin (NS-0200) versus matching placebo in adults 18-75 years with hypertension. Approximately 150 subjects will be screened to randomize \~150 (≈50 per arm) with an expected completer population of \~120. The primary objective is to compare change in mean seated systolic blood pressure from baseline (Day 1) to Week 12 (Day 84) for each NS-0200 dose versus placebo. Secondary outcomes include change in seated diastolic blood pressure and change in body weight. Safety will be monitored through adverse events, labs, vital signs, ECGs, and pregnancy testing.
ClinicalTrials.gov Show glossary Search for terms Hide glossary Study record managers: refer to the Data Element Definitions if submitting registration or results information.
The goal of this study is to determine if NS-0200 can reduce the amount of liver fat in patients diagnosed with non-alcoholic fatty liver disease (NAFLD). This study will compare two doses of NS-0200 to placebo in NAFLD patients.
Study NS-0100-01E is an extension of Study NS-01-0100 designed to assess safety and longer term effect (i.e., additional 8 weeks) of various fixed-dose leucine and metformin combinations (NS-0100) versus standard metformin monotherapy on glycemic control in subjects with type 2 diabetes using HbA1c as the primary endpoint.
The goal of this study is to demonstrate that leucine in combination with a low does of metformin can serve as an adjunct to diet and exercise to improve blood glucose levels in type 2 diabetic subjects. This study will compare three doses of a leucine-metformin combination to the standard metformin dose in controlling blood glucose levels in type 2 diabetic patients.
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
NuSirt Biopharma - Products, Competitors, Financials, Employees, Headquarters Locations Technology Vendors Recent Research Newsletter Media Support Login Who We Serve Function Corporate Strategy Corporate Venture Capital Venture Capital IT Corporate Innovation How VCs Use CB Insights Go to the video gallery → Industries Consumer & Retail Tech Insurance Healthcare Industrials Financial Services Professional Services Professional Services Learn More → Success Stories How We Help Understand Tech Markets Anticipate Competitor Strategy Determine Tech Strategy Connect with Tech Vendors & Par … s include: autosomal recessive disorders diabetes hepatology View Patents Chart Application Date Grant Date Title Related Topics Status 2/7/2018 5/12/2020 Compositions and methods for increasing energy metabolism Phosphodiesterase inhibitors, Piperazines, Diabetes, Transcription factors, Nutrition Grant Application Date 2/7/2018 Grant Date 5/12/2020 Title Compositions and methods for increasing energy metabolism Related Topics Phosphodiesterase inhibitors, Piperazines, Diabet … rase inhibitors, Piperazines, Diabetes, Transcription factors, Nutrition Status Grant Learn more by requesting a demo Latest NuSirt Biopharma News PDE Inhibitors Market Trends 2024: Key Insights and Future Projections by IMR Market Report Feb 25, 2025 According to IMR Market Reports, PDE Inhibitors Market is expected to grow at a significant growth rate, and the analysis period is 2024-2032, considering the base year as 2023. PDE Inhibitors Market research is an ongoing proce … e following categories: By Type: PDE5, PDE4, Viagra, Cialis, Levitra, Others By Application: Genitourinary,Cardiovascular Diseases,Neurological Diseases,Dermatological Disorders,Respiratory Diseases,Other Indications Get up to 20% off on the direct purchase of this report! Competitive Analysis of the market in the report identifies various key manufacturers of the market. We do company profiling for major key players. The research report includes Competitive Positioning, Inve
Checking your browser - reCAPTCHA Checking your browser before accessing pmc.ncbi.nlm.nih.gov ... Click here if you are not automatically redirected after 5 seconds.
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
%PDF-1.4 %���� 607 0 obj > endobj xref 607 85 0000000016 00000 n 0000003019 00000 n 0000003181 00000 n 0000004387 00000 n 0000004536 00000 n 0000004633 00000 n 0000005091 00000 n 0000005570 00000 n 0000005686 00000 n 0000005800 00000 n 0000005912 00000 n 0000006036 00000 n 0000006161 00000 n 0000006615 00000 n 0000006864 00000 n 0000007383 00000 n 0000007638 00000 n 0000009456 00000 n 0000011170 00000 n 0000012457 00000 n 0000014168 00000 n 0000015541 00000 n 0000017078 00000 n 0000017634 00000 n 0000017771 00000 n 0000017910 00000 n 0000018431 00000 n 0000018945 00000 n 0000019201 00000 n 000 … dobj 658 0 obj > endobj 659 0 obj > endobj 660 0 obj > endobj 661 0 obj >stream application/pdf Print 2019-09-26T17:04:49-04:00 2019-09-26T17:04:49-04:00 2019-09-26T16:10:11-04:00 Adobe Illustrator CC 23.0 (Macintosh) uuid:be2339aa-505e-824a-8e6b-b4c33cf69483 xmp.did:d59b9aff-c474-4c7d-9da0-4146d65acc1f uuid:5D20892493BFDB11914A8590D31508C8 proof:pdf uuid:d1c078a0-2746-42b2-b0d1-25aedff8fb1e xmp.did:1b6690ed-28a8-c141-9479-b6a9cf6be651 uuid:5D20892493BFDB11914A8590D31508C8 pr … ��m�K��[�+��? Hz�꒭Uf���p���|k����'8�K�� L� endstream endobj 76 0 obj >stream application/pdf MM-095_InsertArt_PPT 2019-10-18T00:51:28-04:00 2019-10-18T00:51:28-04:00 2019-10-18T00:51:26-04:00 Adobe Illustrator CC 23.1 (Macintosh) uuid:d6bd17f7-5839-f54f-b580-e76568401f47 xmp.did:2df381a7-933a-4663-ad9e-b2c4321c2854 uuid:5D20892493BFDB11914A8590D31508C8 proof:pdf uuid:6ecd5e9b-2e55-8e40-9f31-c35323ba3d16 xmp.did:0ac06c81-7837-4fef-8bb8-992a5afc390e uuid:5D20892493BFDB11914A … ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ��zq����� endstream endobj 96 0 obj >stream application/pdf MM-095_InsertArt_PPT 2019-10-18T00:51:28-04:00 2019-10-18T00:51:28-04:00 2019-10-18T00:51:26-04:00 Adobe Illustrator CC 23.1 (Macintosh) uuid:d6bd17f7-5839-f54f-b580-e76568401f47 xmp.did:2df381a7-933a-4663-ad9e-b2c4321c2854 uuid:5D20892493BFDB11914A8590D31508C8 proof:pdf uuid:6ecd5e9b-2e55-8e40-9f31-c35323ba3d16 xmp.did:0ac06c81-7837-4fef-8bb8-992a5afc390e uuid:5D20892493BFDB11914A … 67-dc558eba086e xmp.did:79B0FB807B2268119109D6C22CD87D3F default converted from application/x-indesign to application/pdf Adobe InDesign CC 14.0 (Macintosh) / 2019-11-10T11:22:38-05:00 application/pdf Adobe PDF Library 15.0 False endstream endobj 122 0 obj > endobj xref 0 607 0000000000 65535 f 0001220584 00000 n 0001221693 00000 n 0001229635 000
%PDF-1.5 %���� 1 0 obj >>> endobj 2 0 obj > endobj 3 0 obj >/Font >/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/MediaBox[ 0 0 960 540] /Contents 4 0 R/Group >/Tabs/S/StructParents 0>> endobj 4 0 obj > stream x���Ko7��� x� �3��A��6���� � �@���*� ��;Õ��jeq/��r8?��9|��K�������seU���ԿӉQFc��x��5j5�N>�R�Y�\�F���{60ƃ�;�^M'L'��řR o���zmk �=8u��t2��I�F#)`767A� hծ[�8�wg�w�Bc��4��44��>h�� �Qhz�փ��8��-j[��O�PS�g0}nD ���nHc�5�Ɂ5_jL�ز��q2���x`�H��G�Vb�UR �~���B�Z$���b��\��Pj�t���8���� �q#��\��d8�Aң�(8��(���d5J�B�Tam| ��A��>�ׄ�k��_&\�n��/���t�Ҡύ�7��N�c U������U:�h+��h��s>%
Checking your browser - reCAPTCHA Checking your browser before accessing pmc.ncbi.nlm.nih.gov ... Click here if you are not automatically redirected after 5 seconds.
10-K 1 vktx-10k_20171231.htm 10-K vktx-10k_20171231.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2017 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM                      TO  &# … 12 months (or for such shorter period that the Registrant was required to submit and post such files).     Yes ☒     No    ☐ Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§229.405) is not contained herein, and will not be contained, to the best of Registrant’s knowledge, in definitive proxy or information statements incorporated by … 11 was submitted in December 2008 by Ligand. The subject of the IND was an application to begin clinical investigations of the drug substance in healthy volunteers. In a Phase 1 clinical trial, VK5211 was shown to be safe and well-tolerated following daily oral administration for 21 days. In this clinical trial, statistically significant increases in lean muscle mass were observed in drug-treated subjects compared to subjects treated with placebo (p=0.047), and posi … se granted under the Master License Agreement. As partial consideration for the grant of the rights and licenses to us under the Master License Agreement, we issued to Ligand at the closing of our initial public offering of our common stock, or the IPO, 3,655,964 shares of our common stock having an estimated aggregate value of $29.2 million. Furthermore, as partial consideration for the grant of the rights and licenses to us under the Master License Agreement, we entere … ment with Ligand (as discussed below). As further partial consideration for the grant of the rights and licenses to us by Ligand under the Master License Agreement, we have agreed to pay to Ligand certain one-time, non-refundable milestone payments in connection with Licensed Products containing (1) VK5211 or any other SARM Compound, in an a
29693876 32853066 0 P3Y us-gaap:OtherAssetsNoncurrent us-gaap:AccountsPayableAndOtherAccruedLiabilities us-gaap:LongTermDebtNoncurrent 0001270073 --12-31 2019 FY false 0001270073 us-gaap:StateAndLocalJurisdictionMember 2019-01-01 2019-12-31 0001270073 us-gaap:DomesticCountryMember 2019-01-01 2019-12-31 0001270073 us-gaap:StateAndLocalJurisdictionMember 2018-01-01 2018-12-31 0001270073 us-gaap:ForeignCountryMember 2018-01-01 2018-12-31 0001270073 us-gaap:DomesticCountryMember 2018-01-01 2018-12-31 0001270073 us-gaap:OtherIncomeMember 2019-01-01 2019-12-31 0001270073 us-gaap:CommonStockMember 20 … 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐ ​ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth com … al of our product candidates, including the regulatory approval of our New Drug Application for NASH; any advisory committee recommendation that our product candidates, including OCA for liver fibrosis due to NASH, should not be approved or approved only under certain conditions; or any determination that the regulatory applications and subsequent information we submit for our product candidates, including OCA for liver fibrosis due to NASH, do not contain adequate … f NASH patients with liver fibrosis. In September 2019, we submitted a New Drug Application (“NDA”) to the FDA seeking accelerated approval of OCA for liver fibrosis due to NASH. In November 2019, the FDA accepted our NDA for filing and granted a priority review designation for OCA for liver fibrosis due to NASH. Under the Prescription Drug User Fee Act (“PDUFA”), the FDA has set a target action date of June 26, 2020 for the completion of its review of … DA for April 22, 2020. In December 2019, we submitted a Marketing Authorization Application (“MAA”) to the European Medicines Agency (“EMA”) seeking conditional approval of OCA for liver fibrosis due to NASH. In January 2020, the EMA validated our MAA and thereby confirmed that our MAA was sufficiently complete to begin th
Taiwan - Biotech Companies - Careers Page About Directory Promoted Listings Purchase Data Drug Pipelines Data Licensing Weekly Update Newsletter Contact Taiwan - Biotech Companies - Career Pages Genome Explorations , Acquired by Tesis Biosciences, Feb 2022 Chordia Therapeutics Fujisawa, Japan Oncology Treatments Tranxenogen , Assets sold in 2004. Website is copyright 2002. No evidence of termination of business, but not likely they are active Gilead Foster City, CA Small Molecules Immulogic Pharmaceutical , Gone, 1999 GenPath Pharmaceuticals , Changed name t … C Cranbury, NJ Pharmaceutical Contract Work Carigent Therapeutics , Had a grant in 2008. No info for a long time BeVivo , Website down Feb 2021 - Aug 2021 PhotoMedex , Sold assets 2016, Website Gone, Dec 2018 Raidium Aubervilliers, France Foundation Model for precision medicine in radiology Vero Biotech Atlanta, GA Nitric Oxide Generation & Delivery Maruho Medical , Website down Apr 2024 - Aug 2024 Resonetics San Diego, CA Contract Me … Suzhou, China RNAi Therapeutics Biopraxis , No website no info. 1996 SBIR grant. Seems to be an umbrella group Oxford Endovascular Oxford, UK Neurovascular Devices CytoImmune Therapeutics Duarte, CA Cancer Immunotherapy Functional Neuromodulation , Shut down Dec 2023; Website under construction Feb 2024 - Mar 2024 Paragon 28 Englewood, CO Foot & Ankle Implants Qx Therapeutics New Haven, CT MAP3K2/3 inhibitor KorvaLabs , Acquired by Cu … on Channel Innovations , Primitive website, no apparent employees. Got $1M SBIR grant in 2013 Manhattan Genomics New York, NY Gene Correction Therapies BioReference Laboratories Elmwood Park, NJ Genetic, Diagnostic Testing Lungpacer Medical Vancouver, BC Diaphragm Pacing Therapy PaxMedica , Website down Apr 2025 - Sep 2025 OrganOx Oxford, UK Organ Transportation Technology Miravo Healthcare , Website down Dec 2023 - May 2024 Canthera … m Therapeutics , Website down Feb 2024 - Jul 2024; Wound healing, may have drug application GeneTether Therapeutics , Renamed Rize Oncology, Jan 2025 Pharmatech , Acquired by Caris Life Sciences, May 2019 Dermira , Bought by Eli Lilly, Feb 2020, $1.1B EyePoint Pharmaceuticals Watertown, MA Miniaturized, sustained-release d
Checking your browser - reCAPTCHA Checking your browser before accessing pmc.ncbi.nlm.nih.gov ... Click here if you are not automatically redirected after 5 seconds.
NuSirt Sciences, Inc Careers, Perks + Culture | Built In Companies Jobs Articles Can't find your company? Create a company profile. View All Jobs Join Log In For Employers Companies NuSirt Sciences, Inc Teams NuSirt Sciences, Inc Save Saved Nashville 3 Total Employees Year Founded: 2007 View Website Overview Jobs Offices Is This Your Company? Claim Profile Pharmaceutical NuSirt is focused on the development of novel drugs for the treatment of diabetes and other metabolic disorders including obesity, arteriosclerosis, and hyperlipidemia. NuSirt Sciences, Inc Offices OnSite Workspace Employ
Tennessee Employers | Biotech Careers Skip to main content Biotech Careers Contact Submit an Employer Contact Add an Employer Search Open main menu Contact Submit an Employer Contact Add an Employer Search Main navigation Careers Job Areas People Articles Videos Biotech Companies Biotech Jobs Business Areas Tennessee Biotech Employers Tennessee has 51 employers in 58 locations View the biotech employers in Tennessee as a map View biotechnology education in Tennessee Displaying 1 - 50 of 58 biotech employer locations Filter the data by: City Employer Business Area(s) 2-yr Grad Any Yes Careers A
Nusirt - Advisory Team | The Org Platform Enrich Pricing Log in Sign up Nusirt Teams Advisory Team Unverified Advisory Team 5 people · 0 jobs The Advisory Team at NuSirt Sciences consists of experienced advisors who provide strategic guidance, industry insights, and expert recommendations to support the development and commercialization of the company's biotechnology products. People ( 5 ) Alan Cherrington Advisor Mary E. Rinella Advisor Naga Chalasani Advisor Orville Kolterman Advisor Zan Fleming Advisor Jobs ( 0 ) No jobs in this team Other teams View all teams Leadership Team 3 peopl
Eric Satz - Director at Nusirt | The Org Platform Enrich Pricing Log in Sign up Nusirt Eric Satz Unverified Eric Satz Director Contact Eric Satz, serves as a Managing Member of the Tennessee Community Ventures Fund, LLC (TNCV), a company he co-founded in 2009, and is Executive Chairman to three TNCV portfolio companies. From 2010 to 2014, he served as Investor, Advisor, and Vice President of Business Development for Panopto, Inc. He co-founded and was Chief Executive Officer of Plumgood Food, LLC from 2004 to 2008. Org chart View org chart This person is not in the org chart Teams View all t
10-K 0001880438 2.0 false FY 0001880438 antx:AnacorLicensingAgreementMember 2022-01-01 2022-12-31 0001880438 us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2022-01-01 2022-12-31 0001880438 antx:IncentiveStockOptionMember antx:TwoThousandTwentyTwoEquityIncentivePlanMember 2022-12-31 0001880438 us-gaap:RedeemableConvertiblePreferredStockMember 2022-01-01 2022-12-31 0001880438 us-gaap:AccountingStandardsUpdate201811Member 2022-12-31 0001880438 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel1Member us-gaap:USTreasurySecuritiesMember us-gaap:FairValueMeasurementsRecurringMember … eding 12 months (or for such shorter period that the Registrant was required to submit such files). Yes ☒ No ☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth compan … l and drug product for launch; • the sufficiency of our existing cash to fund our future operating expenses and capital expenditure requirements; • the accuracy of our estimates regarding expenses, capital requirements and needs for additional financing; • the ability of our pivotal Phase 2/3 clinical trial in mycobacterium avium complex (“MAC”) lung disease to be sufficient for regulatory approval in the United States and Japan and potentia … ate agencies and foundations. In 2022 we received a cost-reimbursement contract award from the National Institute of Allergy and Infectious Diseases (“NIAID”), part of the National Institutes of Health (“NIH”), under which we are able to receive up to $17.8 million in cost reimbursements to advance the development of epetraborole for acute systemic melioidosis and other biothreat pathogens. The below table summarizes our development plans for epetr … 2022; Melioidosis : In September 2022 we received a cost-reimbursement contract award under which we are able to receive up to $17.8 million in non-dilutive funding in the form of cost reimbursements from the NIAID to support preclinical, Phase 1 studies, and other activities to enable advancement of epetraborole into a pivotal Phase 2/3 clinical
NuSirt - Longevity List Sign in or Register Add a listing View all results No results Jobs Database More arrow_drop_down Clinical Trials Newsletter Coworking Events Blog Supporters About Add a listing opening tag is omitted --> tag --> NuSirt Natural compounds that activate sirt1 and sirt3 to treat metabolic disease Website Profile prev next Website Bookmark Share prev next General Headquarters Nashville, Tennessee 37215, United States Founders & Team Michael Zemel Year Founded 2007 Number of employees 10 Company type Private company Funding stage Series C Total funding ($M) 16.0 Investors Hat … with various pharmaceutical agents. The company has protected the discovery and application of this broad based technology platform through an extensive IP portfolio that includes thirteen issued or allowed to date with corresponding patents pending globally. NuSirt has successfully conducted multiple clinical studies that have validated its discovery and demonstrated the value of its intellectual property. Categories Genomics Mitochondria How much is an extra decade of life
Nusirt Sciences, Inc. - Drug pipelines, Patents, Clinical trials - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 04 Mar 2026 Nusirt Sciences, Inc. Holding Company | 2007 | Tennessee, United States | < 10 | nusirt.com Holding Company | 2007 | Tennessee, United States | < 10 | nusirt.com Last update 04 Mar 2026 Overview Pipeline Deal Translational Medicine Profit Grant & Funding(NIH) Investment Financing Overview Tags Endocrinology and Metabolic Disease Small molecule drug Disease domain score A glimpse into the focused therapeutic areas No Data Technolo … itions of over 360K organizations with Synapse. login or view full example data Grant & Funding(NIH) Access more than 2 million grant and funding information to elevate your research journey. login or view full example data Investment Gain insights on the latest company investments from start-ups to established corporations. login or view full example data Financing Unearth financing trends to validate and advance investment opportunities. login or view full example data
FDA grants fast track designation for potential NAFLD regimen Close Ask Healio AI New! News News CME CME Clinical Guidance Clinical Guidance Community Community Healio AI Healio AI AI Healio AI Mobile Account Account Anonymous User Log In Log In Log Out Log Out News News CME CME Clinical Guidance Clinical Guidance Community Community Healio AI Healio AI AI Healio AI Mobile Specialties Choose a specialty All Specialties Allergy/Asthma Cardiology Dermatology Endocrinology Gastroenterology Hematology/Oncology Hepatology Infectious Disease Nephrology Neurology Ophthalmology Optometry Orthopedics P … ep it going! View Recommended CME Edit Goal Close Reminder from Healio CME Your deadline is here. You need {credits} Credits to reach your goal. View Recommended CME View goal Would you like to receive email reminders to complete your saved activities from Healio CME? Yes No Activity saved! You'll receive reminders to complete your saved activities from Healio CME. Unsubscribe Confirm your account You're logged in as . Please review your account details and complete any missi
Advisors Archives - Metabolics Pharma Skip to content Toggle Navigation Science ENT-03 ENT-21 ENT-AD Pipeline Pipeline People Advisors Board of Directors Leadership News Publications Contact Alexander Fleming, MD Alexander Fleming, MD Dr. Alexander Fleming is Founder and Executive Chairman of Kinexum, a company of professionals from across the world with diverse expertise in developing drugs, biotech products, medical devices and digital health technologies. He is also Executive Vice-President of Tolerion, a biotechnology company developing disease-modifying treatments for type 1 diabetes and
NuSirt Sciences, Inc. Company Profile: Financials, Valuation, and Growth | PrivCo Sign In Create Free Account PrivCo NuSirt Sciences, Inc. NuSirt Sciences, Inc. Nashville, TN Watchlist Export About Financials People Deals Funding About NuSirt Sciences, Inc. Company overview NuSirt Sciences, Inc. is a privately-held company that operates in the biotechnology industry. NuSirt Sciences, Inc. was founded in 2007 by Michael Zemel. NuSirt Sciences, Inc. headquarters are located in Nashville, Tennessee. Keywords Revenue Revenue EBITDA EBITDA Valuation Valuation Income Statement Line Item 2024 2023 20
Michael Zemel | NuSirt Sciences Skip to content Home About Us Pipeline Expand MAFLD and MASH Obesity Type 2 Diabetes and Pre-Diabetes Hypertension NuSirt Health Publications Intellectual Property Contact Toggle Menu Michael Zemel Dr. Michael Zemel is the the Co-Founder and Chief Scientific Officer at NuSirt Biopharma and Chief Scientific Officer at Kinexum. At NuSirt, he develops and runs the discovery R&D program in metabolic health, leading to clinical stage asset development in obesity, diabetes and NASH. He also leads the NuSirt clinical program development and regulatory effort throug
Publications | NuSirt Sciences Skip to content Home About Us Pipeline Expand MAFLD and MASH Obesity Type 2 Diabetes and Pre-Diabetes Hypertension NuSirt Health Publications Intellectual Property Contact Toggle Menu Publications Norton EM , Plumb S , Shane D , et al. Leucine, pyridoxine and resveratrol supplementation alter metabolic parameters in ponies with equine metabolic syndrome . Equine Vet J . 2025 . https://doi.org/10.1002/evj.70135 . Rebello CJ, Zemel MB, Kolterman O, Fleming GA, Greenway FL. Leucine and sildenafil combination therapy reduces body weight and metformin enhances the eff
Pipeline | NuSirt Sciences Skip to content Home About Us Pipeline Expand MAFLD and MASH Obesity Type 2 Diabetes and Pre-Diabetes Hypertension NuSirt Health Publications Intellectual Property Contact Toggle Menu Pipeline NuSirt’s technology platform focuses on activating sirtuin pathways with specific combinations of leucine and other natural compounds and drugs. Scientific literature has established that activation of the Sirt1 and Sirt3 pathways can significantly improve insulin sensitivity and reduce risks associated with metabolic disorders like fatty liver disease, diabetes, high blood pre
NuSirt Sciences - Hatteras investor login contact team dedicated funds news portfolio Operator of a biopharmaceutical agency intended to offer drugs for the treatment of diabetes and other metabolic disorders. The company’s platform combines natural compounds with various pharmaceutical agents, enabling healthcare professionals to use natural compounds to create synergy with known pharmaceuticals to prevent and treat chronic diseases resulting from over-nutrition and aging. VISIT WEBSITE Active , Bio Tech , HVP IV , Portfolio back to portfolio contact © hatteras venture partners | all ri
Portfolio Companies – ChiesiVentures Skip to content Menu Home Investment Focus Small Molecules and Biologics Advanced Therapies Reformulation Technological Platform and Devices Disease discovery, diagnosis and management Investments Portfolio Companies Strategic Connections Pappas Capital News Connect Team and Governance Submit your business plan Portfolio Companies Portfolio Companies Chiesi Ventures invests in innovative biotech companies developing treatments for rare diseases. MIRUM PHARMACEUTICALS Mirum Pharmaceuticals is developing a compound, maralixibat, to treat Alagille syndro … Companies Strategic Connections Pappas Capital News Connect Team and Governance Submit your business plan
NuSirt Biopharma Raises $6 Million in Series C Funding - Hatteras investor login contact team dedicated funds news portfolio NuSirt Biopharma Raises $6 Million in Series C Funding Portfolio Company News 5/18/15 Financing led by Hatteras Venture Partners accelerates Type 2 diabetes program Company launches new clinical program in non-alcoholic fatty liver disease NASHVILLE, Tenn.–( BUSINESS WIRE )– NuSirt Biopharma , a company dedicated to improving the lives of those with chronic metabolic diseases, announced it has raised $6 million in Series C financing, of which $2 million has been fu … ional 86 million age 20 and older have pre-diabetes . NuSirt’s first technology application explores combining leucine with metformin, the most widely-prescribed Type 2 diabetes medication, to control blood sugar. Metformin is effective when taken as directed, but many people who are prescribed the drug experience side effects, such as gastrointestinal issues, muscle pain, fatigue and headaches, which can cause them stop taking it or reduce how much medication they take. Pre- … n humans this fall. NuSirt currently has protected the discovery and commercial application of its technology through an IP portfolio that includes three issued/allowed patents and 9 active patent families. About NuSirt Biopharma NuSirt Sciences, Inc., headquartered in Nashville, is dedicated to improving the lives of people living with chronic metabolic diseases. The company has a unique technology platform that uses a patented combination of leucine, an essential amino acid
Intellectual Property | NuSirt Sciences Skip to content Home About Us Pipeline Expand MAFLD and MASH Obesity Type 2 Diabetes and Pre-Diabetes Hypertension NuSirt Health Publications Intellectual Property Contact Toggle Menu Intellectual Property NuSirt is the sole owner of the patents and patent applications covering its discovery and commercialization (Patents). Twenty-four US patents across seven different patent families have been issued or allowed to date, with corresponding patents pending globally. The Patents have layered claims sets designed to maximize protection and value for the com
%PDF-1.4 %���� 2183 0 obj > endobj xref 2183 28 0000000016 00000 n 0000001907 00000 n 0000002070 00000 n 0000003093 00000 n 0000003208 00000 n 0000003788 00000 n 0000004415 00000 n 0000004887 00000 n 0000005543 00000 n 0000006138 00000 n 0000006665 00000 n 0000006871 00000 n 0000007224 00000 n 0000007570 00000 n 0000007992 00000 n 0000008615 00000 n 0000009218 00000 n 0000010911 00000 n 0000011036 00000 n 0000011767 00000 n 0000012059 00000 n 0000012379 00000 n 0000012458 00000 n 0000015240 00000 n 0000262387 00000 n 0000262731 00000 n 0000001693 00000 n 0000000873 00000 n trailer ]/Prev 34175 … ?(�İ��Q�+� ���.� ��z��3�t h �Ћ��rF�Yv�5�M������ > endobj 9 0 obj >stream application/pdf ncn-connectivity-background-transparent-bc 2020-02-21T13:27:09-06:00 2020-02-21T13:27:09-06:00 2020-02-21T13:27:08-06:00 Adobe Illustrator 24.0 (Macintosh) uuid:5e7f477a-b6bf-a94a-86bc-d57285c2fc95 xmp.did:2d570b92-432a-48d9-8a30-fbefdef7f248 uuid:5D20892493BFDB11914A8590D31508C8 proof:pdf xmp.iid:adf6d66d-0ab0-4634-8fda-b056b4534b97 xmp.did:adf6d66d-0ab0-4634-8fda-b056b4534b97 uui … E\(Ѓ� ��HU��l����� qʱ2 endstream endobj 30 0 obj > endobj 31 0 obj >stream application/pdf ncn-connectivity-background-transparent-bc 2020-02-21T13:27:09-06:00 2020-02-21T13:27:09-06:00 2020-02-21T13:27:08-06:00 Adobe Illustrator 24.0 (Macintosh) uuid:5e7f477a-b6bf-a94a-86bc-d57285c2fc95 xmp.did:2d570b92-432a-48d9-8a30-fbefdef7f248 uuid:5D20892493BFDB11914A8590D31508C8 proof:pdf xmp.iid:adf6d66d-0ab0-4634-8fda-b056b4534b97 xmp.did:adf6d66d-0ab0-4634-8fda-b056b4534b97 uui … �]����> �f��aˀ�%� {�� *�2�3J --- S�R�+�KRs� > endobj 63 0 obj >stream application/pdf ncn-connectivity-background-transparent-bc 2020-02-21T13:27:09-06:00 2020-02-21T13:27:09-06:00 2020-02-21T13:27:08-06:00 Adobe Illustrator 24.0 (Macintosh) uuid:5e7f477a-b6bf-a94a-86bc-d57285c2fc95 xmp.did:2d570b92-432a-48d9-8a30-fbefdef7f248 uuid:5D20892493BFDB11914A8590D31508C8 proof:pdf xmp.iid:adf6d66d-0ab0-4634-8fda-b056b4534b97 xmp.did:adf6d66d-0ab0-4634-8fda-b056b4534b97 uui … "X�B8j%�S��Αceg�7�c�3;]2�����6L�Nl�q2��Yey!�� l > endobj 85 0 obj >stream application/pdf ncn-connectivity-background-transparent-bc 2020-02-21T13:27:09-06:00 2020-02-21T13:27:09-06:00 2020-02-21T13:27:08-06:00 Adobe Illustrator 24.0 (Macintosh) uuid:5e7f477a-b6bf-a94a-86bc-d57285c2fc95 xmp.did:2d570b92-432a-48d9-8a30-fbefdef7f248 uuid:5D20
S-1 1 tm2225873-1_s1.htm S-1 tm2225873-1_s1 - none - 15.2188172s TABLE OF CONTENTS As filed with the Securities and Exchange Commission on September 16, 2022 Registration No. 333-     ​ ​ ​ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ​ ​ FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ​ NEUROBO PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) ​ ​ Delaware (State or other jurisdiction of incorporation or organization) ​ ​ 2834 (Primary … red, and we do not expect a market to develop. In addition, we do not intend to apply for the listing of the Series B Convertible Preferred Stock or the warrants on any national securities exchange or other trading market. Without an active trading market, the liquidity of the warrants will be limited. Except as otherwise indicated, all share and per share information in this prospectus gives effect to the reverse stock split of our outstanding common stock, which was ef … al of at least $15 million in a Qualified Financing upon which Dong-A will fund an additional $15 million, which is being sold in the private offering. DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both NASH and T2D. Agonism of GPR119 in the gut promotes the release of key gut peptides GLP-1, GIP, and PYY. These peptides play a further role in glucose metabolism, lipid m … as a going concern; ​ • NeuroBo will need additional financings to fund operations and such additional financings may cause dilution to existing stockholders, restrict NeuroBo’s operations or require NeuroBo to relinquish its technologies; ​ • The timing and costs related to the clinical development of NeuroBo’s products are difficult to predict, and any delays in NeuroBo’s clinical trials may lead to a delay in the submission of mar … Agreement and we expect that our cash and cash equivalents will be adequate to fund operations into the first quarter of 2023. If we consummate this offering and the consummate the 2022 License Agreement, we expect that our costs will increase significantly as we advance the development of these product candidates through clinical trials and oth
- YouTube Info Presse Urheberrecht Kontakt Creator Werben Entwickler Impressum Verträge hier kündigen Nutzungsbedingungen Datenschutz Richtlinien & Sicherheit Wie funktioniert YouTube? Neue Funktionen testen © 2026 Google LLC
Checking your browser - reCAPTCHA Checking your browser before accessing pmc.ncbi.nlm.nih.gov ... Click here if you are not automatically redirected after 5 seconds.
NuSirt Biopharma | MTEC MTEC Focus Areas Who we serve Solicitations Patents About Us Explore Join MTEC Log In Life Sciences / Companies NuSirt Biopharma Nusirt is a research organization focused on exploring the interactions and effects of compounds like leucine, metformin, sildenafil, and others on metabolic health, insulin sensitivity, lipid metabolism, and related conditions such as non-alcoholic fatty liver disease and obesity. The organization conducts various scientific studies and abstracts to advance understanding in these areas. Industries biotechnology clinical-trials diabetes Nr. of
Collaboration will help patients with liver disease, those needing biopsy Close Ask Healio AI New! News News CME CME Clinical Guidance Clinical Guidance Community Community Healio AI Healio AI AI Healio AI Mobile Account Account Anonymous User Log In Log In Log Out Log Out News News CME CME Clinical Guidance Clinical Guidance Community Community Healio AI Healio AI AI Healio AI Mobile Specialties Choose a specialty All Specialties Allergy/Asthma Cardiology Dermatology Endocrinology Gastroenterology Hematology/Oncology Hepatology Infectious Disease Nephrology Neurology Ophthalmology Optometry O … ep it going! View Recommended CME Edit Goal Close Reminder from Healio CME Your deadline is here. You need {credits} Credits to reach your goal. View Recommended CME View goal Would you like to receive email reminders to complete your saved activities from Healio CME? Yes No Activity saved! You'll receive reminders to complete your saved activities from Healio CME. Unsubscribe Confirm your account You're logged in as . Please review your account details and complete any missi
About Us - NuSirt Health Skip to content Home About Us LEUSIX ® Introducing LEUSIX® Clinical Data Modest lifestyle changes About GLP-1 Drugs No-Risk 30-Day Challenge LEUSIX ® for Dogs Resources Publications Reviews Q&A Buy Now Contact Us Menu Home About Us LEUSIX ® Introducing LEUSIX® Clinical Data Modest lifestyle changes About GLP-1 Drugs No-Risk 30-Day Challenge LEUSIX ® for Dogs Resources Publications Reviews Q&A Buy Now Contact Us Home About Us LEUSIX ® Introducing LEUSIX® Clinical Data Modest lifestyle changes About GLP-1 Drugs No-Risk 30-Day Challenge LEUSIX ® for Dogs Resourc … t Us Who Are We? NuSirt was originally founded by drug developers who wanted to apply their expertise to dietary supplements. Our current team consists of: G. Alexander Fleming, MD CEO and Director G. Alexander Fleming, MD, NuSirt CEO, is Founder and Executive Chairman of Kinexum, a former FDA official responsible for landmark drug approvals and former CEO of Tolerion. Thomas Seoh, JD COO and Director Thomas Seoh, JD, NuSirt COO, is CEO of Kinexum and previously CEO of Faust
NuSirt Biopharma, Inc. - Drug pipelines, Patents, Clinical trials - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 08 May 2025 NuSirt Biopharma, Inc. Private Company Private Company Last update 08 May 2025 Overview Pipeline Deal Translational Medicine Profit Grant & Funding(NIH) Investment Financing Overview Related 2 Drugs associated with NuSirt Biopharma, Inc. Sildenafil/Metformin/Leucine Target PDE5A x PRKAB1 Mechanism PDE5A inhibitors [+1] Active Org. Nusirt Sciences, Inc. Originator Org. Nusirt Sciences, Inc. Active Indication Diabetes Mellitus, Type 2 I … 23, Takeda announced that the FDA has accepted for review its Biologics License Application (BLA) for the investigational subcutaneous formulation of ENTYVIO as a maintenance treatment for adults with moderately to severely active Crohn's disease, following induction therapy with the intravenous version of ENTYVIO. In April 2023, Takeda announced that the FDA has accepted for review its resubmitted Biologics License Application (BLA) for the investigational subcutaneous formu … itions of over 360K organizations with Synapse. login or view full example data Grant & Funding(NIH) Access more than 2 million grant and funding information to elevate your research journey. login or view full example data Investment Gain insights on the latest company investments from start-ups to established corporations. login or view full example data Financing Unearth financing trends to validate and advance investment opportunities. login or view full example data
NuSirt Biopharma, Inc. - Drug pipelines, Patents, Clinical trials - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 08 May 2025 NuSirt Biopharma, Inc. Private Company Private Company Last update 08 May 2025 Overview Pipeline Deal Translational Medicine Profit Grant & Funding(NIH) Investment Financing Overview Related 2 Drugs associated with NuSirt Biopharma, Inc. Sildenafil/Metformin/Leucine Target PDE5A x PRKAB1 Mechanism PDE5A inhibitors [+1] Active Org. Nusirt Sciences, Inc. Originator Org. Nusirt Sciences, Inc. Active Indication Diabetes Mellitus, Type 2 I … 23, Takeda announced that the FDA has accepted for review its Biologics License Application (BLA) for the investigational subcutaneous formulation of ENTYVIO as a maintenance treatment for adults with moderately to severely active Crohn's disease, following induction therapy with the intravenous version of ENTYVIO. In April 2023, Takeda announced that the FDA has accepted for review its resubmitted Biologics License Application (BLA) for the investigational subcutaneous formu … itions of over 360K organizations with Synapse. login or view full example data Grant & Funding(NIH) Access more than 2 million grant and funding information to elevate your research journey. login or view full example data Investment Gain insights on the latest company investments from start-ups to established corporations. login or view full example data Financing Unearth financing trends to validate and advance investment opportunities. login or view full example data
OWL Metabolomics Inks Diagnostics Deal with NuSirt Biopharma clinicalomicsprowebdirectory Facebook Linkedin Twitter News Topics Informatics Molecular Dx Patient Care Oncology Precision Medicine Translational Research Magazine Browse Issues Subscribe Subscribe Get Inside Precision Medicine Magazine Get Inside Precision Medicine eNewsletters Multimedia Webinars Summits Podcasts Videos Inside Precision Medicine Live Learning Labs eBooks Search Facebook Linkedin Twitter Sign in Welcome! Log into your account your username your password Forgot your password? Get help Privacy Policy Password recover … ion Assumptions News & Features | ASGCT 2026: Timothy Yu Wins Jerry Mendell Award For N-of-1 Therapies News & Features | Asthma Drug Formoterol Shows Potential to Reverse MASH News & Features | Immune Mapping Links Sex-Specific Genetics to Autoimmune Disease News & Features | Mayo Clinic's REDMOD AI Doubles Early Detection Sensitivity in Pancreatic Cancer News & Features | Early Glucagon Elevation Linked to MASLD in Type 2 Diabetes Podcast Series Behind th … istosomiasis Transmission Assumptions ASGCT 2026: Timothy Yu Wins Jerry Mendell Award For N-of-1 Therapies Asthma Drug Formoterol Shows Potential to Reverse MASH Immune Mapping Links Sex-Specific Genetics to Autoimmune Disease Explore About Us Contact Us Advertise Advertising Terms and Conditions Privacy Policy CCPA – Do not sell my personal information Get IPM Magazine Get IPM eNewsletters Related Sites Genetic Engineering & Biotechnology News Genetic Testing 
NuSirt receives $2.1M NIH grant for TRIPLN(tm) trial | Thomas Seoh posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to … p Content People Learning Jobs Games Join now Sign in NuSirt receives $2.1M NIH grant for TRIPLN(tm) trial Thomas Seoh 8mo Edited Report this post Kinexum subsidiary NuSirt is building momentum! This $2.1M NIH SBIR grant will fund a P2 hypertension trial for NuSirt's novel TRIPLN(tm) (leucine, metformin and sildenafil), building on successful P2 trials in obesity and fatty liver. We believe TRIPLN(tm) has the potential to become an accessible better metformin for broad cardio … ansfer 44,413 followers 8mo NuSirt Sciences Inc secured the #SBIR #NIH Phase II grant for the clinical validation of NS-0200, a drug to treat hypertension. Alien is proud to have supported their funding success. Read more about their groundbreaking work: https://lnkd.in/dW3BRwe2 #Alien #NIH #Hypertension 12 1 Comment Like Comment Share Copy LinkedIn Facebook X Shivam Sharma 8mo Report this comment Thank you, Thomas! Truly appreciate the kind words and the collaboration! Like
%PDF-1.4 1 0 obj > endobj 3 0 obj > endobj 4 0 obj [/Pattern /DeviceRGB] endobj 5 0 obj > endobj 12 0 obj > /ExtGState > /Pattern > /Font > /XObject > >> endobj 13 0 obj [ ] endobj 10 0 obj > stream x��]M�ܸ�ϯ�s���}F�� �� �a����&0�E�=�ߏ�Eu����[OeJ���C���b��ի}���_l�=|���s����M�UE��o��u;��i���MU�����o7�7�o>�|h���}�췛��������?ÿ�ܚ�����y�����e�{�a?�n@|���]7��-��n@�7��^�� ���ߛ�c���?o~k�7��B�Cc����~��m�e����}� .{�{�LJ��?��>�S����/��?�"�����w��Ɣ�O�m��n��>}�����b������u�|�zcLV��n�v��� [ܮ�̬�w�~h��3yVV������=ծ� ~P�~Pgu������ �l7��O�5$W�6E�n�?�mx4w���ޫ.+~�� �}�ɂ����9A�� `'x� ��y�b.��x��
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
S-1/A 1 d211954ds1a.htm S-1/A S-1/A Table of Contents As filed with the Securities and Exchange Commission on March 21, 2022. Registration No. 333-263295 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 AN2 Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 2834 82-0606654 (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial … States. We recently received clearance of our Investigational New Drug, or IND, application by the FDA to begin our Phase 1 renal impairment study, for which enrollment commenced in February 2022, and plan to initiate patient enrollment in our Phase 2/3 pivotal clinical trial in the first half of 2022, with topline results for the Phase 2 part of the trial anticipated in the middle of 2023 and for the Phase 3 part of the trial anticipated in the middle of 2024, pend … reement, or the Global Health Agreement, with Adjuvant Global Health Technology Fund L.P. and Adjuvant Global Health Technology Fund DE L.P., or together, Adjuvant, in connection with Adjuvant’s investment of $12.0 million in our Series A and Series B redeemable convertible preferred stock financings. Pursuant to the Global Health Agreement, we must use reasonably diligent endeavors to develop epetraborole for melioidosis, tuberculosis, and any other mutually agreed-upon … of renal function (normal to severe). We recently received clearance of our IND application by the FDA to begin this Phase 1 renal impairment study, for which enrollment commenced in February 2022, with topline results anticipated in the second half of 2022. We have designed a Phase 2/3 pivotal clinical trial that, based on our three interactions to date with the FDA to discuss the design, including discussions regarding our nonclinical microbiology, toxicology, and pharmacol … expanding our pipeline of product candidates; and ∎ Apply our expertise in antimicrobial drug design and development to other global health problems. Our Team Our team is led by Eric Easom, M.B.A., M.Eng., our co-founder, president, and chief executive officer. Mr. Easom has over 31 years of leadership experience
%PDF-1.6 %���� 131 0 obj > endobj 172 0 obj >/Filter/FlateDecode/ID[ ]/Index[131 92]/Info 130 0 R/Length 167/Prev 391557/Root 132 0 R/Size 223/Type/XRef/W[1 3 1]>>stream h�bbd```b``1���A$S��� >stream h�b```b``f`c`�fd@AV�( ���� ,�O5?r��d� �������@5k�{�6O`@���+wu�.]����()ݽ��n�R�Ԁ^ G7��=�n�YT.Z:�v�"&C_����F��]�:�6mC��!�ش�����^1� Q\Dzkn������ &��BӢ�ޝ����b\��� >>> endobj 133 0 obj >/Font >/ProcSet[/PDF/Text]/Properties >/XObject >>>/Rotate 0/TrimBox[0.0 0.0 594.0 783.0]/Type/Page>> endobj 134 0 obj >stream H�\��n�@��y��L."l g�fĔ��n �ɕ��� ��N}�R���w �>��u};}\�����2�� … ) 2016-08-12T10:53:06+05:30 2016-08-12T10:53:05+05:30 2016-08-12T10:53:06+05:30 application/postscript Shyneer S. orchid_logo.eps uuid:645c43a3-feca-4153-b60b-9a2a9dfc6428 xmp.iid:6915BBD94C60E611AD72B662A92B5C94 xmp.did:6915BBD94C60E611AD72B662A92B5C94 saved xmp.iid:40338E756D63E411A01CE06922E7E506 2014-11-05T17:29:33+05:30 Adobe Illustrator CS4 / converted from application/postscript to application/vnd.adobe.illustrator converted from application/postscript to application/v … ) 2016-08-12T10:53:06+05:30 2016-08-12T10:53:05+05:30 2016-08-12T10:53:06+05:30 application/postscript Shyneer S. orchid_logo.eps uuid:645c43a3-feca-4153-b60b-9a2a9dfc6428 xmp.iid:6915BBD94C60E611AD72B662A92B5C94 xmp.did:6915BBD94C60E611AD72B662A92B5C94 saved xmp.iid:40338E756D63E411A01CE06922E7E506 2014-11-05T17:29:33+05:30 Adobe Illustrator CS4 / converted from application/postscript to application/vnd.adobe.illustrator converted from application/postscript to application/v … ) 2016-08-12T10:53:06+05:30 2016-08-12T10:53:05+05:30 2016-08-12T10:53:06+05:30 application/postscript Shyneer S. orchid_logo.eps uuid:645c43a3-feca-4153-b60b-9a2a9dfc6428 xmp.iid:6915BBD94C60E611AD72B662A92B5C94 xmp.did:6915BBD94C60E611AD72B662A92B5C94 saved xmp.iid:40338E756D63E411A01CE06922E7E506 2014-11-05T17:29:33+05:30 Adobe Illustrator CS4 / converted from application/postscript to application/vnd.adobe.illustrator converted from application/postscript to application/v … ) 2016-08-12T10:53:06+05:30 2016-08-12T10:53:05+05:30 2016-08-12T10:53:06+05:30 application/postscript Shyneer S. orchid_logo.eps uuid:645c43a3-feca-4153-b60b-9a2a9dfc6428 xmp.iid:6915BBD94C60E611AD72B662A92B5C94 xmp.did:6915BBD94C60E611AD72B662A92B5C94 saved xmp.iid:40338E756D63E411A01CE06922E7E506 2014-11-05T17:29:33+05:30 Adobe Illustrator CS4
Home - NuSirt Health Skip to content Home About Us LEUSIX ® Introducing LEUSIX® Clinical Data Modest lifestyle changes About GLP-1 Drugs No-Risk 30-Day Challenge LEUSIX ® for Dogs Resources Publications Reviews Q&A Buy Now Contact Us Menu Home About Us LEUSIX ® Introducing LEUSIX® Clinical Data Modest lifestyle changes About GLP-1 Drugs No-Risk 30-Day Challenge LEUSIX ® for Dogs Resources Publications Reviews Q&A Buy Now Contact Us Home About Us LEUSIX ® Introducing LEUSIX® Clinical Data Modest lifestyle changes About GLP-1 Drugs No-Risk 30-Day Challenge LEUSIX ® for Dogs Resources P
XBRL Viewer Please enable JavaScript to use the EDGAR Inline XBRL Viewer.
#pulmonarydiseases #cardiovasculardiseases #hypertension #clinicaltrial #fda #phase2 #tiprelestat #stanforduniversity | Ines-Regina Buth LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Co … t this post Kinexum subsidiary NuSirt is building momentum! This $2.1M NIH SBIR grant will fund a P2 hypertension trial for NuSirt's novel TRIPLN(tm) (leucine, metformin and sildenafil), building on successful P2 trials in obesity and fatty liver. We believe TRIPLN(tm) has the potential to become an accessible better metformin for broad cardiometabolic health. Meanwhile, on NuSirt's supplement side, LEUSIX(R), an entry into the GLP-1 companion product market, with RCT data sh … ansfer 44,412 followers 8mo NuSirt Sciences Inc secured the #SBIR #NIH Phase II grant for the clinical validation of NS-0200, a drug to treat hypertension. Alien is proud to have supported their funding success. Read more about their groundbreaking work: https://lnkd.in/dW3BRwe2 #Alien #NIH #Hypertension 12 1 Comment Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in Alien Technology Transfer 44,412 followers 8mo Report this post NuSirt Sciences Inc … lowers 8mo Report this post NuSirt Sciences Inc secured the #SBIR #NIH Phase II grant for the clinical validation of NS-0200, a drug to treat hypertension. Alien is proud to have supported their funding success. Read more about their groundbreaking work: https://lnkd.in/dW3BRwe2 #Alien #NIH #Hypertension 25 Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in 2,896 followers 775 Posts View Profile Connect Explore content categories Career Productivity
#pulmonarydiseases #cardiovasculardiseases #pulmonaryarterialhypertension #clinicaltrial #fda #phase2 #tiprelestat #stanforduniversity | tiakis Biotech AG LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join Linke … hare Copy LinkedIn Facebook X To view or add a comment, sign in i&i Biotech Fund 2,018 followers 8mo Report this post 🔥 We’re proud to see our portfolio company Vasa Therapeutics reach this important milestone — FDA clearance of their IND application for VS-041 in HFpEF. 💊 After successful completion of our Phase 1 trial in healthy volunteers earlier this year, Vasa is excited to initiate a Phase 1c study of VS-041 in participants affected with HFpEF and elevated serum … 2 followers 8mo Edited We are thrilled to announce that the FDA has cleared IND application for a Phase 1c study with our lead asset, VS-041 in participants with Heart Failure with Preserved Ejection Fraction (HFpEF). The study will assess the safety and tolerability of VS-041 in the target patient population. Additionally, the study has potential to establish a novel precision medicine paradigm in the high-risk HFpEF patients identified by a high level of serum endotrophin. … t this post Kinexum subsidiary NuSirt is building momentum! This $2.1M NIH SBIR grant will fund a P2 hypertension trial for NuSirt's novel TRIPLN(tm) (leucine, metformin and sildenafil), building on successful P2 trials in obesity and fatty liver. We believe TRIPLN(tm) has the potential to become an accessible better metformin for broad cardiometabolic health. Meanwhile, on NuSirt's supplement side, LEUSIX(R), an entry into the GLP-1 companion product market, with RCT data sh … ansfer 44,412 followers 8mo NuSirt Sciences Inc secured the #SBIR #NIH Phase II grant for the clinical validation of NS-0200, a drug to treat hypertension. Alien is proud to have supported their funding success. Read more about their groundbreaking work: https://lnkd.in/dW3BRwe2 #Alien #NIH #Hypertension 12 1 Comment Like Comment Share Copy Linke
Type 2 Diabetes and Pre-Diabetes | NuSirt Sciences Skip to content Home About Us Pipeline Expand MAFLD and MASH Obesity Type 2 Diabetes and Pre-Diabetes Hypertension NuSirt Health Publications Intellectual Property Contact Toggle Menu Type 2 Diabetes and Pre-Diabetes Diabetes affects over 38 million Americans. Type 2 diabetes mellitus (T2DM) is responsible for over 90% of these cases. Reports suggest that metformin is the most frequently prescribed T2DM medication due to its ability to lower glucose effectively while producing few side effects. In TRIPLN ® , NuSirt combines metformin with L-le
Sirtuin Activation for Aging and Overnutrition | NuSirt Sciences Skip to content Home About Us Pipeline Expand MAFLD and MASH Obesity Type 2 Diabetes and Pre-Diabetes Hypertension NuSirt Health Publications Intellectual Property Contact Toggle Menu Sirtuin activation for diseases of aging and overnutrition NuSirt Sciences combines established pharmaceuticals and natural products to activate the sirtuin pathway, thereby addressing conditions associated with aging and overnutrition. We target cardiometabolic diseases, including metabolic-associated fatty liver disease (MAFLD), metabolic function … TRIPLN ® in hypertension will begin in late 2026, backed by a $2.1 million SBIR grant. Readout will take place in 2027. LEUSIX ® NuSirt also produces LEUSIX ® , a dietary supplement supporting cardiometabolic health and weight management. In a phase 2 clinical trial of people with obesity, participants who took LEUSIX ® and made mild lifestyle changes lost 9% body weight in 6 months. Lean muscle was preserved, suggesting that LEUSIX ® could be a supplement or substitute to GL
NuSirt Plans Clinical Trial In Non-Alcoholic Fatty Liver Disease - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Drug Development NuSirt Plans Clinical Trial In Non-Alcoholic Fatty Liver Disease October 8, 2015 | 4 min read Twitter LinkedIn Facebook Email Print Company raises additional Series C financing to expand research and development for its patented technology NASHVILLE, Tenn.--( BUSINESS WIRE )-- NuSirt … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
New Study: Nusirt Technology Could Aid In Treatment Of Non-Alcoholic Steatohepatitis (NASH) And Type 2 Diabetes - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Tren … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Drug Development New Study: Nusirt Technology Could Aid In Treatment Of Non-Alcoholic Steatohepatitis (NASH) And Type 2 Diabetes May 27, 2015 | 4 min read Twitter LinkedIn Facebook Email Print Recently published research shows that a combination of NuSirt technology and low doses of marketed pharmaceu … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
New Study: NuSirt Technology Demonstrates Potential As New Type 2 Diabetes Therapy - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Canc … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search New Study: NuSirt Technology Demonstrates Potential As New Type 2 Diabetes Therapy June 25, 2015 | 4 min read Twitter LinkedIn Facebook Email Print NASHVILLE, Tenn.--( BUSINESS WIRE )-- NuSirt Biopharma today announced that new research published in the July 2015 issue of Metabolism demonstrates that its patented techno … luding this summer. NuSirt currently has protected the discovery and commercial application of its technology through an IP portfolio that includes three issued/allowed patents and 9 active patent families. About Diabetes According to the American Diabetes Association, more than 29 million Americans have diabetes, and an additional 86 million Americans age 20 and older have prediabetes. It is currently the seventh leading cause of death in the U.S., and its complications incl … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Local Companies at the 2016 Career Symposium | BRET Career Development ASPIRE Program | Vanderbilt University Skip to main content About Us The ASPIRE Team About the BRET Office of Career Development ASPIRE Program Annual Report Calendar Make an Appointment Individual Appointment Advising Frequently Asked Questions General FAQs Professionalism Policy Best Practices: Attire Giving Connect Online Stay Connected Upcoming Events Blog E-Newsletter Open Jobs for Trainees LinkedIn Annual Report Individual Appointment Advising Our Programs & Resources Events Upcoming Events Learn about our events … V / Resume Drop In Clinic ASPIRE Path in Molecular Medicine Richard M. Caprioli Award for Technology Education Resources Resources ASPIRE Grant Repository ASPIRE CV/Resume Repository Path to Career Resources Job Search Navigator Borrow from the Career Development Library Blog Beyond the Lab: See and Listen Funding Resources For Partners For Faculty and Training Grants For Employers For Students and Postdocs For Alumni Alumni & Outcomes Where Are Our Alumni? Get Involved w … in the corporate, academic, governmental and non-profit sectors. http://www.cet-fund.com/ Cumberland Pharmaceuticals Cumberland Pharmaceuticals is a specialty pharmaceutical company that acquires, develops and commercializes branded prescription products designed to improve quality of care and address unmet medical needs.With a focus on underserved niche markets, including hospital acute care and gastroenterology, we deliver products that serve patients in the U.S. market.Cum … ilt Office of Research and the NIH sponsored Clinical and Translational Science Award (CTSA), the mission of the institute is to transform the way ideas and research discoveries make their way from origin to patient care. This is accomplished using a multi-faceted approach: through collaboration with a wide variety of research partners; by training, nurturing and rewarding participating researchers; by funding research; by developing new and innovative ways to involve the com … stration of educational policies, programs, or activities; admissions policies; scholarship and loan programs; athletic or other University-administered programs; or employment. Accessibility information . Vanderbilt®, Vanderbilt University®, V Oak Leaf Design®, Star V Design® and Anchor Down® are trademarks of The Vanderbilt